Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
Aim. Sacubitril-valsartan has proven beneficial in heart failure with reduced ejection fraction. Guidelines recommend initiating half-dose sacubitril-valsartan before up-titration even to patients already on target dose angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers...
Main Authors: | Helena Norberg, Ellinor Bergdahl, Krister Lindmark |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi-Wiley
2019-01-01
|
Series: | Cardiovascular Therapeutics |
Online Access: | http://dx.doi.org/10.1155/2019/6745074 |
Similar Items
-
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
by: Ramesh R. Dargad, et al.
Published: (2018-07-01) -
Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01) -
Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
by: Katie L. Peppin, et al.
Published: (2020-01-01) -
Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
by: Hyoeun Kim, et al.
Published: (2021-08-01) -
Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan
by: Lena Holmlund, et al.
Published: (2020-03-01)